MetaVia Inc MTVA

NAS: MTVA | ISIN: US64132R4048 6/06/2025

0,692 USD (+0,30%)

(+0,30%) 6/06/2025

Toon enkel gratis nieuws

14 mei 2025 · MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update · Persbericht

9 mei 2025 · MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules · Persbericht

7 mei 2025 · MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 · Persbericht

23 april 2025 · MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 · Persbericht

22 april 2025 · MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential · Persbericht

15 april 2025 · MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability · Persbericht

20 maart 2025 · MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe